[16048] in Public-Access_Computer_Systems_Forum
Read the news now. It could be a big watch tomorrow morn
daemon@ATHENA.MIT.EDU (1shl2y)
Sat Aug 27 22:45:22 2005
From: "1shl2y" <1shl2y@exprom.co.uk>
To: <dburbach@mit.edu>
Date: Sat, 27 Aug 2005 19:45:11 -0800
Message-ID: <002701c5ab7a$828548e0$8f2f5af1@JUIF>
MIME-Version: 1.0
Content-Type: multipart/alternative;
boundary="----=_NextPart_000_0024_01C5AB3F.D62670E0"
This is a multi-part message in MIME format.
------=_NextPart_000_0024_01C5AB3F.D62670E0
Content-Type: text/plain;
charset="us-ascii"
Content-Transfer-Encoding: 7bit
EMERGING =3D
GROWTH ALERT
Issue: 108457
August 2005
Worldwide Biotech & Pharmaceutical Co
Rapid Growth Alert
Symbol:
WWBP
52 Week
Range
2.00 - 11.00
Shares
Float:
25,000,000
Current
Price:
$3.73
12
Mo.Target Price
$22.00
Growth
Rating
High
Breaking News Alerts!
Up
0.73
(24.33%)
Get In While You Still Can!
Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'
Thursday August 25, 9:00 am ET
Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''
ADVERTISEMENT
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''
About World Intellectual Property
Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.
About Worldwide Biotech & Pharmaceutical =3D
Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good =
=3D
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen =
=3D
and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing =
=3D
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.
The Company expects if it is able to raise =3D
additional funds it will purchase additional equipment, otherwise, it will =
=3D
not. The Company further does not expect any significant change in the =3D
number of employees unless it accomplishes a merger with another company. =
=3D
We intend to become a supplier of HCV virus for our internal needs and =3D
for sale to third parties, such as research institutions and =3D
pharmaceutical companies. We intend to continue to develop and refine our =
=3D
ELISA kit and Rapid Test products and produce those products for sale. We =
=3D
will need to pursue our marketing plans to insure both recognition of our =
=3D
product and to create demand. We will continue to develop, refine and =3D
pursue patents on our Traditional Chinese Medicine (TCM) products. =3D
However, in order to facilitate the transition from a company focused on =
=3D
research and development to a company that produces and sells its products =
=3D
and services will be dependent upon our ability to raise additional =3D
capital during the next twelve months. We will pursue capital raising =3D
either through conventional loans from various financial institutions or =
=3D
through an offering of our shares after the filing of a registration =3D
statement with the Securities and Exchange Commission. We anticipate that =
=3D
in order to finance our business plans and accomplish our goals, we will =
=3D
need to raise approximately $15,000,000 from the second quarter of year =
=3D
2005 to the end of year 2006. We expect to finish the filing of a =3D
registration statement with the Securities and Exchange Commission by the =
=3D
end of the third quarter of 2005. The capital raise is intended to be =3D
accomplished largely through conventional loans from Chinese banks with =
=3D
our current property as the collateral before the registration statement =
=3D
is effective. We intend to utilize these funds for production ($1.4 =3D
million for year 2005 and $2.44 million for year 2006), R & D ($0.3 =3D
million for year 2005 and $0.73 million for year 2006), administration =3D
($0.55 million for year 2005 and $1.77 million for year 2006), =3D
acquisitions and mergers of various companies that will foster and promote =
=3D
our business objectives ($7.8 million for year 2006). At present, based =
=3D
upon our current cash position, it is estimated that we can meet our =3D
expenses as they currently exist for the next 16 months if we are able to =
=3D
negotiate extensions of certain outstanding loans. There are two loans =3D
currently outstanding that will be due this year, $604,040 due on May 28, =
=3D
2005 and $1,207,554 due in July 2005. We anticipate that we will be able =
=3D
to negotiate a one-year extension on each of these loans, but this has not =
=3D
yet been accomplished. We expect that our expenses for current operations =
=3D
will be similar to that of last year where we spent $684,149. Accordingly, =
=3D
based upon current operations, we can sustain ourselves for a little over =
=3D
7 months. Net cash used in investing activities for the year ended =3D
December 31, 2004 was $1,105,559 as compared to net cash used in investing =
=3D
activities for the year ended December 31, 2003, of $532,016. For the year =
=3D
ended December 31, 2004, we used cash for capital expenditures of =3D
$1,226,478 offset by cash provided from the sale of marketable securities. =
=3D
For the year ended December 31, 2003, we used cash for capital =3D
expenditures of $532,106.
------=_NextPart_000_0024_01C5AB3F.D62670E0
Content-Type: text/html;
charset="us-ascii"
Content-Transfer-Encoding: quoted-printable
<html>
<body>
<table width=3D"654" border=3D"1" align=3D"center" cellpadding=3D"0" =
cellspacing=3D"0" bordercolor=3D"#000000">
<tr>
<td width=3D"650"><table width=3D"650" border=3D"0" align=3D"center" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" style=3D"padding:8px" height=3D"46" =
bgcolor=3D"#0000FF">
<p><font size=3D"4"><strong><font color=3D"#FFFFFF">EMERGING =
GROWTH ALERT</font></strong></p></td>
</tr>
<tr>
<td bgcolor=3D"#000000" style=3D"padding:2px">
<font color=3D"#FFFFFF">Issue: 108457</font></td>
<td bgcolor=3D"#000000" style=3D"padding:2px"><div =
align=3D"right">
<font color=3D"#FFFFFF">August 2005</font></div></td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:10px"><div =
align=3D"left"></div>
<div align=3D"left"></div>
<table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"0" cellspacing=3D"0">
<tr>
<td><table width=3D"325" border=3D"1" align=3D"right" =
cellpadding=3D"3" cellspacing=3D"0">
<tr bgcolor=3D"#003399">
<td colspan=3D"2" bgcolor=3D"#0000FF"><b><em>
<font size=3D"2" face=3D"Arial, Helvetica, sans-serif" =
color=3D"#FFFFFF">
Worldwide Biotech & Pharmaceutical Co</font></em></b><font =
color=3D"#FFFFFF" size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong><br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"2" =
color=3D"#FFFFFF">
Rapid Growth Alert</font></strong></td>
</tr>
<tr>
<td width=3D"53%"><font size=3D"2" face=3D"Arial, =
Helvetica, sans-serif">
Sy<b></b>mbol: </font></td>
<td width=3D"47%"><em><b>
<font face=3D"Arial, Helvetica, sans-serif" =
size=3D"2">WWBP</font></b></em></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">52 Week
Range</font></td>
<td>2.00 - 11.00</td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Sha<b></b>res
Float: </font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">
25,000,000</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">Current
Price:</font></td>
<td> <font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"><strong>
$3.73</strong></font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">12
Mo.Target Price</font></td>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif">$22.00</font></td>
</tr>
<tr>
<td><font size=3D"2" face=3D"Arial, Helvetica, =
sans-serif"> Growth
Rating</font></td>
<td>High</td>
</tr>
</table></td>
</tr>
</table>
<p><em>
<font color=3D"#FF0000" size=3D"4" face=3D"Arial, Helvetica, =
sans-serif"><strong>
Breaking News Alerts!<br>
<br>
</strong></font><strong>
<font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#FF0000">
Up</font><font face=3D"Arial, Helvetica, sans-serif" size=3D"4" =
color=3D"#CC0000">
</font></strong></em><b style=3D"color: #FF0000"><font size=3D"4">0.73
(24.33%)<br>
<br>
Get In While You Still Can!</font></b><em><strong><font face=3D"Arial, =
Helvetica, sans-serif" color=3D"#CC0000" size=3D"3"><br>
<br>
</font></strong><font size=3D"3" face=3D"Arial, Helvetica, sans-serif">
<b>Worldwide Biotech & Pharmaceutical Obtains the China Patent
Golden Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'</b></font><font size=3D"2" =
face=3D"Arial, Helvetica, sans-serif"><br>
<br>
<font color=3D"#FF0000">Thursday August 25, 9:00 am ET <br>
</font><br>
<font color=3D"#0000FF"><b>Marks the Highest Award Over the Past 10
Years in the Biomedical Sciences Industry in China</b> </font><br>
<br>
<br>
XI'AN, China, Aug. 25 /Xinhua-PRNewswire/ -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP - News; ''WWBP'')
has obtained the China Patent Golden Medal for ''the Intact
Hepatitis C Virus (HCV) and Method for Culturing HCV in Vitro by
Cell Culture.''<br>
ADVERTISEMENT<br>
<br>
<br>
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in vitro by Cell Culture'' was awarded the Chinese
Patent by China Patent Bureau on October 23rd, 2002. The patent was
then awarded the prestigious China Patent Golden Medal (Chinese
Patent No. 01124001.6) in the 8th China Patent Assessment organized
by both General World Intellectual Property Organization (WIPO) and
the China Patent Office. Importantly, this patent was recognized by
the World Intellectual Property Organization (WIPO), issued as an
outstanding Chinese Patented Invention, and was the highest award
issued for achievements in the biomedical sciences industry over the
past 10 years in China.<br>
<br>
''We are highly encouraged with our patent which is recognized by
the WIPO and it is such a great achievement for the whole company.
It's a great milestone,'' said WenXia Guo, CEO and President of WWBP,
''the success of this patented invention leads our company to a
worldwide market, we will continue our development and research of
new inventions and bring health to every customer.''<br>
<br>
<font color=3D"#0000FF"><b>About World Intellectual Property
Organization (WIPO)</b></font><br>
<br>
The World Intellectual Property Organization (WIPO) is an
international organization dedicated to promoting the use and
protection of works of the human spirit. These works -- intellectual
property -- are expanding the bounds of science and technology and
enriching the world of the arts. Through its work, WIPO plays an
important role in enhancing the quality and enjoyment of life, as
well as creating real wealth for nations. With headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United Nations system of organizations. It administers 23
international treaties dealing with different aspects of
intellectual property protection.<br>
<br>
<font color=3D"#0000FF"><b>About Worldwide Biotech & Pharmaceutical =
Company</b></font><br>
<br>
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech company with top-ranking pharmaceutical R&D abilities, Good =
Manufacturing Practices (GMP) licensed manufacturing facilities and
a well-established marketing network in China and Southeast Asia.
The product range of WWBP covers Hepatitis C Virus (HCV) products,
diagnostic medicines and Over-The-Counter (OTC) drugs. WWBP
currently possesses 35,940 square meters of land and 5,359 square
meters of GMP standard facilities. With strong pharmaceutical R&D
abilities especially in the HCV field, WWBP has been known as the
first biotech company in the world to hold the technology of
culturing intact HCV in vitro by cell culture.<br>
<br>
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is expected to bring WWBP considerable gross sale revenue each year
and greatly strengthen the company's R&D on anti-HCV drug screen =
and
HCV human vaccine. WWBP had successfully reached two Memoriam of
Understanding of Merger Agreements with pharmaceutical companies in
China, all of which have scalable production and well-established
sales networks, and the acquiring is expected to be finished before
the end of September 2005. The acquisitions will strengthen WWBP's
R&D abilities and production scale, as well as extend its marketing =
network throughout China and Southeast Asia. WWBP has been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.</font></p>
</ol> </em> </td>
</tr>
<tr>
<td colspan=3D"2" style=3D"padding:15px"><p align=3D"justify">
<font color=3D"#FFFFFF">The Company expects if it is able to raise =
additional funds it will purchase additional equipment, otherwise, it will =
not. The Company further does not expect any significant change in the =
number of employees unless it accomplishes a merger with another company. =
<br>We intend to become a supplier of HCV virus for our internal needs and =
for sale to third parties, such as research institutions and =
pharmaceutical companies. We intend to continue to develop and refine our =
ELISA kit and Rapid Test products and produce those products for sale. We =
will need to pursue our marketing plans to insure both recognition of our =
product and to create demand. We will continue to develop, refine and =
pursue patents on our Traditional Chinese Medicine (TCM) products. =
However, in order to facilitate the transition from a company focused on =
research and development to a company that produces and sells its products =
and services will be dependent upon our ability to raise additional =
capital during the next twelve months. We will pursue capital raising =
either through conventional loans from various financial institutions or =
through an offering of our shares after the filing of a registration =
statement with the Securities and Exchange Commission. We anticipate that =
in order to finance our business plans and accomplish our goals, we will =
need to raise approximately $15,000,000 from the second quarter of year =
2005 to the end of year 2006. We expect to finish the filing of a =
registration statement with the Securities and Exchange Commission by the =
end of the third quarter of 2005. The capital raise is intended to be =
accomplished largely through conventional loans from Chinese banks with =
our current property as the collateral before the registration statement =
is effective. We intend to utilize these funds for production ($1.4 =
million for year 2005 and $2.44 million for year 2006), R & D ($0.3 =
million for year 2005 and $0.73 million for year 2006), administration =
($0.55 million for year 2005 and $1.77 million for year 2006), =
acquisitions and mergers of various companies that will foster and promote =
our business objectives ($7.8 million for year 2006). At present, based =
upon our current cash position, it is estimated that we can meet our =
expenses as they currently exist for the next 16 months if we are able to =
negotiate extensions of certain outstanding loans. There are two loans =
currently outstanding that will be due this year, $604,040 due on May 28, =
2005 and $1,207,554 due in July 2005. We anticipate that we will be able =
to negotiate a one-year extension on each of these loans, but this has not =
yet been accomplished. We expect that our expenses for current operations =
will be similar to that of last year where we spent $684,149. Accordingly, =
based upon current operations, we can sustain ourselves for a little over =
7 months. <br>Net cash used in investing activities for the year ended =
December 31, 2004 was $1,105,559 as compared to net cash used in investing =
activities for the year ended December 31, 2003, of $532,016. For the year =
ended December 31, 2004, we used cash for capital expenditures of =
$1,226,478 offset by cash provided from the sale of marketable securities. =
For the year ended December 31, 2003, we used cash for capital =
expenditures of $532,106. </font></p></td>
</tr>
</table></td>
</tr>
</table>
<br></body>
</html>
------=_NextPart_000_0024_01C5AB3F.D62670E0--
